Juststocks interview, page-31

Just some questions/thoughts:

1. What is the actual cash balance at the moment?

2. What is the runway of cash burn that we will have moving forward? Were going to be fully funded (with the trial still going on) until CY26 after the $13m CR.

3. WASTING $513K OF COMPANY MONEY?! (Half a million dollars!) - I missed this but why did we need short term funding? The below quote is from October Quarterly Update.

In summary...
- started the qtr with $11.867m
- ended with $8.014m (including the $1.7m advanced funds from the short term funded)
- doesn't include the funds raised via the Insto and SPP raises (that money will be in the Dec Qtr)
- paid 15.6% PA or 1.33 per month PLUS $13K in fees for the facility
- DID RECEIVE $2.3m BUT WASTED $513K on short term funding/loan

'During the quarter, the Company entered into a short-term funding facility with Radium Capital (Facility) secured against its 2024 RDTI. The Facility allowed Percheron to access up to 80% of its accrued RDTI rebate early, as determined by a Radium-approved accounting firm based, on eligible expenditure. The drawn down amount was repayable on receipt of the RDTI rebate and attracted an interest charge of 1.33% per month. The Company received $1.7 million in advance funding from Radium Capital which was repaid on the date that proceeds from the R&D Refund were received.'

At the time of the quarterly, the company had $8m in the bank so the $1.7m was not needed. The finance cost 1.3% per month (or 15.6% PA). Fees of $13K based on the financial report. That is BAD cash management when the funds were not required!? Half a million lost for no apparent reason or need.

4. What stage and how fast can PER pivot to ATL1103 for growth disorders in pituitary gland? (Seems like the logical pivot to me other than Autoimmune Epilepsy which is in preclincal vs Stage 2 for ATL1103). What would the trial runway look like? Will the DMD trial enable faster progress?

5. What was the total cost to get ATL1103 to the same stage with Avicursen ? ATL1103 is at stage 2A already? DMDs 2B trial cost around $4m a qtr? (based on Oct 24 report). If PER have effectively half OR more in the bank already then PER might be looking at bounce in SP??